Loading...
Market
Dominant Narcolepsy Treatment Company by End of 2025?
2
Resolution / Starting Odds
Avadel Pharmaceuticals • 25%
Jazz Pharmaceuticals • 25%
Another Company • 25%
No Dominant Player • 25%
Market share reports from healthcare market research firms
Story
FDA Approves AbbVie’s Vyalev for Parkinson’s on 3rd Attempt, Avadel’s LUMRYZ (CIII) for Narcolepsy
Oct 17, 2024, 02:15 PM
The U.S. Food and Drug Administration (FDA) has approved AbbVie's Vyalev™ (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion for adults with advanced Parkinson's disease. This approval marks a significant milestone for AbbVie, following previous rejections, and is the third attempt for the company. Additionally, the FDA has approved Avadel Pharmaceuticals' LUMRYZ™ (sodium oxybate) extended-release oral suspension (CIII) for the treatment of cataplexy or excessive daytime sleepiness in patients aged 7 years and older with narcolepsy. This approval broadens the use of LUMRYZ and intensifies competition with treatments from Jazz Pharmaceuticals.
View original story
Similar markets
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
Eli Lilly • 25%
Eisai and Biogen • 25%
Other companies • 25%
No dominant company • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Kisunla™ • 33%
Leqembi • 33%
Other/new drugs • 33%
Ascendis Pharma • 25%
Takeda • 25%
Another existing company • 25%
A new entrant • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Pfizer • 25%
Other • 25%
Zepbound • 25%
CPAP Machines • 25%
Other Pharmaceuticals • 25%
Surgical Treatments • 25%
Biogen • 25%
Roche • 25%
Novartis • 25%
Other • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Kisunla™ > Leqembi • 25%
Leqembi > Kisunla™ • 25%
Kisunla™ and Leqembi have equal market share • 25%
Other treatments lead • 25%